We are international
Donate
TEXT SIZE   
   back

ASH 2011: Dr. San Miguel - Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
Jesús F San Miguel, MD PhD
Hospital Clinico Universitario
Salamanca, Spain
12.07.11

Be the first to comment

 related articles